
Objective To assess associations of primary-tumor shear wave elastography (SWE) with tumor size and pathologically confirmed pelvic lymph node metastasis in cervical cancer with maximum tumor diameter (Dmax) > 2 cm. Methods This single-center ambispective cohort study included 81 surgical patients (41 retrospectively and 40 prospectively enrolled) with pathological nodal assessment and 61 nonsurgical patients with radiological nodal assessment. SWE was performed within 7 days before treatment. A maximum elasticity (Emax)–Dmax model was developed and internally evaluated in surgical patients, then applied unchanged to nonsurgical patients. The incremental value of Emax beyond nodal imaging and Dmax was explored. Results Sixteen surgical patients had pathologically confirmed pelvic lymph node metastasis. Emax correlated with Dmax (Spearman ρ = 0.288; P = 0.009) and remained associated with nodal metastasis after adjustment for Dmax (odds ratio per 10 kPa, 1.202; 95% confidence interval, 1.052–1.403; P = 0.006). Model discrimination, measured by the area under the receiver operating characteristic curve (AUC), was 0.773 (apparent), 0.758 (bootstrap-corrected), and 0.742 (mean cross-validated). Mean cross-validated sensitivity and specificity were 63.5% and 67.6%. Against the radiological reference standard, the nonsurgical AUC was 0.659, with 89.5% sensitivity and 19.0% specificity. Adding Emax to nodal imaging and Dmax increased bootstrap-corrected AUC from 0.821 to 0.877. Conclusion Higher Emax was associated with pathologically confirmed pelvic lymph node metastasis after adjustment for tumor size. The model showed moderate internal discrimination, while its potential incremental value requires independent evaluation in cohorts with pathological confirmation.
Objectives: To evaluate the discriminatory performance of seven complete blood count (CBC)-derived inflammatory indices for preeclampsia (PE) and their incremental value beyond a primary maternal clinical comparator. Methods: This retrospective cohort study included singleton pregnancies with routine CBC testing between 26.0 and 36.9 weeks of gestation at a tertiary hospital in Thailand. Pregnancies with PE or eclampsia were compared with normotensive pregnancies. Discrimination was assessed using receiver operating characteristic analysis and logistic regression. Incremental value beyond a model comprising maternal age, body mass index, gestational age at CBC measurement, primigravidity, and pregestational diabetes was evaluated, with false discovery rate correction for multiple testing. Results: Among 8982 pregnancies, 276 (3.1%) were complicated by PE or eclampsia. CBC testing occurred at a median gestational age of 32.1 weeks. Individual indices showed limited discrimination, with AUCs ranging from 0.438 to 0.513 in the primary direction. NLR, MLR, and SIRI were lower among pregnancies with PE. After adjustment, SIRI reached nominal statistical significance, while NLR and MLR showed similar inverse estimates; none remained significant after false discovery rate correction. The primary maternal clinical comparator had an AUC of 0.723. Adding any individual index increased the AUC by no more than 0.0037 and provided minimal incremental net benefit. Conclusions: CBC-derived inflammatory indices showed limited standalone discrimination for PE and negligible incremental value beyond the primary maternal clinical comparator. These findings do not support their use as standalone or incremental markers of PE risk at this gestational window.
Background Diethylstilbestrol (DES) is a potent synthetic estrogen implicated in endometrial carcinogenesis through estrogen receptor (ER)-dependent mechanisms. However, the temporal relationship between DES exposure, estrogen receptor alpha (ERα) expression, and histopathological progression of endometrial lesions remains incompletely defined in vivo. Methods An experimental in vivo study was conducted using 32 eight-week-old female mice randomly assigned to eight groups, including two untreated controls and six DES-treated groups with varying exposure and observation durations. DES was administered at 1000 µg according to predefined schedules. Uterine tissues were examined histopathologically using HE staining, and ERα expression was evaluated by immunohistochemistry using the modified Remmele Immunoreactive Score. Statistical analyses included one-way ANOVA with Tukey post hoc testing, Kruskal–Wallis and Mann–Whitney U tests, and path analysis to assess mechanistic relationships. Results ERα expression differed significantly among groups, with the highest expression observed in mice receiving prolonged DES exposure followed by extended observation. Histopathological evaluation demonstrated a clear progression from normal endometrium in control groups to higher-grade lesions in DES-treated groups, with severe (Grade 3) changes predominating in high exposure cohorts. Path analysis revealed a significant association between DES exposure and ERα expression, as well as a positive effect of ERα on EC development. Conclusions DES promotes endometrial carcinogenesis through ERα dependent mechanisms in vivo. Increased ERα expression parallels histopathological progression, and mechanistic analysis confirms ERα as a key mediator linking synthetic estrogen exposure to tumor development. These findings underscore the central role of estrogen signaling in DES-induced EC.
Background: Bacterial vaginosis (BV) is the most prevalent vaginal infection among reproductive-age women and is associated with increased susceptibility to gynecological complications. Current antibiotic treatments achieve high initial cure rates but show high rates of recurrence, partly due to their inability to remove persistent biofilms. p Hyph is a novel, non-antibiotic treatment that lowers vaginal pH, promoting Lactobacillus growth and biofilm disruption. Objective: To evaluate the immediate and long-term effects of p Hyph on the vaginal microbiome, BV resolution, and symptom reduction. Study design: In a randomized, controlled, partially blinded study, 61 women with clinically diagnosed BV were randomized to immediate (IT, n = 35) or delayed (DT, n = 26) treatment. Vaginal swabs were collected before treatment, after 6 days, and during maintenance to Day 70. Microbiome composition was analyzed using a qPCR panel targeting 47 bacterial and 6 fungal species. Results: Compared to controls , p Hyph reduced the abundance of multiple BV-associated species and increased Lactobacillus iners following 6-day treatment (median 8.96 ×10 3 [Q1–Q3: 3.10 ×10 3 –2.72 ×10 4 ] vs. median 9.44 × 10² [Q1–Q3: 0.00–4.29 × 10 ³] normalized qPCR counts, p < 0.05). Additionally, p Hyph reduced BV-related symptoms, particularly fishy odor (p < 0.05). Treatment promoted a shift to CST III microbiome composition, and maintenance dosing was associated with sustained Lactobacillus abundance up to Day 70. Conclusions: p Hyph shows potential as an alternative BV treatment by reducing BV-associated pathogens while promoting lactobacilli. Extended dosing may enhance microbiome stability.